Showing 1781-1790 of 4063 results for "".
- Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defect (PCED)https://modernod.com/news/amber-ophthalmics-announces-positive-topline-phase-2-data-evaluating-nexagon-for-the-treatment-of-persistent-corneal-epithelial-defect-pced/2481332/Amber Ophthalmics announced positive topline results from the phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of Nexagon (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (P
- Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Studyhttps://modernod.com/news/melt-pharmaceuticals-melt-300-achieves-primary-sedation-endpoint-in-phase-2-pivotal-efficacy-and-safety-study/2481307/Melt Pharmaceuticals announced topline results of its phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the
- Cognition Therapeutics Presents Data Supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-presents-data-supporting-a-phase-2-clinical-trial-with-ct1812-in-geographic-atrophy-secondary-to-dry-amd/2481270/Cognition Therapeutics announced that the scientific rationale, supporting proof-of-concept data and design of the planned phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) will be communicated in an oral presentation at the
- MediPrint Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Assethttps://modernod.com/news/mediprint-ophthalmics-announces-it-has-initiated-its-sight-2-phase-2b-clinical-study-for-its-lead-asset/2481231/MediPrint Ophthalmics announced it has initiated its SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating
- Aramis Biosciences Completes Enrollment of its Phase 2 Clinical Trial Evaluating A197 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-completes-enrollment-of-its-phase-2-clinical-trial-evaluating-a197-for-the-treatment-of-dry-eye-disease/2481219/Aramis Biosciences announced the completion of enrollment in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease. “We are very pleased to have completed the enrollment of our phas
- Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-announces-positive-phase-3-topline-results-for-nt-501-implant-in-macular-telangiectasia-type-2/2481217/Neurotech Pharmaceuticals announced positive topline results in two replicative phase 3 clinical trials with their investigational encapsulated cell therapy (ECT) for the treatment of Macular telangiectasia type 2 (MacTel), an orphan, slowly progressive degenerative disease of the macula that res
- Unity Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DMEhttps://modernod.com/news/unity-biotechnology-announces-positive-24-week-data-from-phase-2-behold-study-of-ubx1325-in-patients-with-dme/2481214/Unity Biotechnology announced that the key safety and efficacy endpoints were met at 24 weeks in the phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). The company intends to initiate a pivotal study in DME in the second half of 2023. At 24 weeks af
- Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meetinghttps://modernod.com/news/tarsus-to-present-additional-saturn-2-pivotal-phase-3-trial-data-at-the-american-academy-of-optometry-2022-annual-meeting/2481189/Tarsus Pharmaceuticals announced that additional efficacy results from the Saturn-2 pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming American Academy of Optometry 2022 Annual Meeting in San D
- OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-therapeutics-announces-first-patient-dosed-in-ott166-phase-2-dream-clinical-trial-for-diabetic-retinopathy/2481009/OcuTerra Therapeutics announced that the first patient was dosed in its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) or mild proli
- Tarsus Announces Positive Topline Data from Saturn-2 Phase 3 Trial of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis/2480827/Tarsus Pharmaceuticals announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis. With these